ATLAS ACS 2-TIMI 51 was a phase III, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating an oral, direct factor Xa inhibitor (rivaroxaban) in subjects following an acute coronary syndrome. Subjects received low-dose aspirin therapy (75 to 100 mg/day), and enrollment was stratified based upon the intent of the investigator to administer a thienopyridine [Stratum 1 (aspirin only) and Stratum 2 (aspirin plus a thienopyridine)]. Two different doses of rivaroxaban were tested: 2.5 mg twice a day and 5.0 mg twice a day.
MAIN RESULTS:
Rivaroxaban in patients with a recent acute coronary syndrome

N Engl J Med. 2012 Jan 5;366(1):9-19.
PRESENTATIONS
TIMI 51 Slides
Atlas ACS2-TIMI 51 Poster (Alkhalfan, AHA 2019)